BioTheranostics gets OK to distribute breast cancer Dx in N.Y.

07/17/2014 | GenomeWeb Daily News (free registration)

BioTheranostics has received the go-ahead to distribute its Breast Cancer Index in New York. The molecular diagnostic assay measures a patient's risk of recurrent estrogen receptor-positive breast cancer and determines whether extended endocrine treatment will benefit the patient.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX